CBT Pharmaceuticals, Inc.
5976 W. Las Positas Boulevard
About CBT Pharmaceuticals, Inc.
CBT Pharma is an emerging life sciences oncology company focused on developing innovative medicines targeting the growth and proliferation of cancer cells for which available treatments are inadequate. The company was founded in 2016 with headquarters in California with global partners and a subsidiary in Asia. Our pipeline is comprised of four development-stage assets – an oral agent that specifically targets cancer metastasis, a pre-clinical candidate that targets uncontrolled growth signaling pathways, and two investigational products that restore the body’s immune system to recognize and kill cancer cells.
Founders: Guo-Liang Yu and Sanjeev Redkar
CEO: Sanjeev Redkar, PhD, MBA
Executive Vice President and COO: Gavin Choy, PharmD, MBA
18 articles with CBT Pharmaceuticals, Inc.
CBT Pharmaceuticalstoday announced the initiation of the APOLLO Oncology Clinical Trials Program.
CBT Pharmaceuticals Strengthens Management Team with the Appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced a new global leadership structure and the appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing.
CBT Pharmaceuticals Receives First Australian Ethics Approval to Initiate APOLLO-1 Phase 1/2 Clinical Trial for Hepatocellular and Renal Cell Carcinoma
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced the receipt of ethics approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for its planned APOLLO-1 clinical trial.
CBT Pharmaceuticals Initiates Phase 1b Clinical Trial for Anti-PD-1 Antibody CBT-501-01 (genolimzumab injection) in Patients with Advanced Solid Tumors
CBT Pharmaceuticals today announced the continuation of the CBT-501 Phase 1 clinical trial with the initiation of the Phase 1b segment of the study in patients with select advanced or relapsed/recurrent solid tumors.
CBT Pharmaceuticals and CrystalGenomics Announce Partnership for Co-development of Global Immuno-Oncology Therapy
CBT Pharmaceuticals (CBT) and CrystalGenomics, Inc., (KOSDAQ:083790) today announced a co-development agreement for an investigational combination therapy of CBT-501 and CG200745 across a variety of solid tumors with high unmet medical needs.
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.
CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of Its Multi-Tyrosine Kinase Inhibitor, CBT-102, at AACR Annual Meeting 2018
CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, presented preclinical in-vivo data and animal safety pharmacology studies of CBT-102
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
Crown Bioscience and a global drug discovery and development services company announced a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company.
Based in Santa Clara, California, CBT Pharma was spun out of Crown Bioscience with four development-stage assets in the oncology space.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity of its PD-L1 Immunotherapy Antibody, CBT-502 at the AACR-NCI-EORTC International Conference on Molecular Target and Cancer Therapeutics
CBT Pharma presented preclinical data which showed that CBT-502 efficiently inhibited binding of PD-L1 with no binding to PD-L2, CD28, ICOS or CTLA4.
CBT Pharma Announces First U.S. Patient Dosed In Phase 1 Clinical Trial Of C-Met Inhibitor, CBT-101, For Advanced Solid Tumors With C-Met Dysregulation
CBT Pharma today announced that the first subject has been dosed in the Phase I multi-center study, CBT-101-01 which is an important milestone for CBT and its employees.
CBT Pharma Appoints Nationally Recognized Leaders In Oncology To Newly Established Scientific Advisory Board
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity Of Its Highly Specific C-MET Inhibitor, Bozitinib (CBT-101), At AACR Annual Meeting 2017
CBT Pharma Release: First-in-Human Genolimzumab Phase I Study Initiated To Assess Safety And Preliminary Efficacy In Patients With Select Advanced Solid Tumors
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity Of Its Programmed Death-1 Antibody, CBT-501, At ASCO-SITC Clinical Oncology Symposium
CBT Pharma Closes $9.75 Million Series A Financing Led By OrbiMed For Development Of Oncology Pipeline